BBIO
BridgeBio Pharma, Inc.
$67.37
-0.35%
$13.2B
No data for this timeframe.
Vol
Market Cap$13.2B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$2.1B
Inst. Activity4 buys / 1 sells
Insider Activity0B / 17S
Insider Net $-$11.0M
SEC Reports9
Press Releases6
Congressional4 trades
Recent Activity
Nov 27, 2026
fda_pdufa
PDUFA: BBIO — BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) — 2026-11-27
FDA target action date 2026-11-27 for BBIO (BridgeBio Pharma, Inc.). Drug: BBP-418. Indication: limb
Jun 5, 2026
Insider
Kumar Neil sold 7,147 shares
Chief Executive Officer @ $67.20 ($480.3K)
Jun 4, 2026
Insider
Kumar Neil sold 2,200 shares
Chief Executive Officer @ $65.72 ($144.6K)
May 27, 2026
Press
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of Novembe
Impact 8/10
May 26, 2026
SEC
Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day
CLUSTER — Impact 5/10
May 21, 2026
SEC
BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 shares of common stoc
144 — Impact 3/10
May 21, 2026
Insider
Kumar Neil sold 2,256 shares
Chief Executive Officer @ $67.57 ($152.4K)
May 19, 2026
SEC
A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 earnings release and
CLUSTER — Impact 3/10
Price Targets
$102.71
+51.8% upside
Strong Buy
Current $67.68
Low $76.00
Median $100.00
High $157.00
23 analysts
$76.00
$157.00
Analyst Ratings
8Strong Buy
19Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Canaccord Genuity | INITIATE | Buy |
| May 28, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 26, 2026 | Raymond James | DOWNGRADE | Outperform → Market Perform |
| May 19, 2026 | Citigroup | INITIATE | Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.56 ▲ +6.9% | $-0.70 — $-0.42 | 41% YoY | 6 |
| Next Q | $-0.46 ▲ +6.8% | $-0.57 — $-0.37 | 36% YoY | 6 |
| Current FY | $-2.17 ▼ -6.3% | $-2.62 — $-1.49 | 43% YoY | 8 |
| Next FY | $0.33 ▲ +21.8% | $-1.30 — $2.12 | 115% YoY | 7 |
Latest Reports
BULLISH
Press
8/10
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of Novembe
May 27, 2026
BEARISH
CLUSTER
5/10
Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day
May 26, 2026
NEUTRAL
144
3/10
BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 shares of common stoc
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.3B | — |
| FMR LLC | $182.8M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $150.3M | ADD |
| TWO SIGMA INVESTMENTS, LP | $148.9M | DOUBLED |
| NORGES BANK | $116.8M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Kumar Neil | SELL | $480.3K |
| Jun 4, 2026 | Kumar Neil | SELL | $144.6K |
| May 21, 2026 | Kumar Neil | SELL | $152.4K |
| May 18, 2026 | Trimarchi Thomas | SELL | $677.7K |
| May 16, 2026 | Apuli Maricel | F | $311.7K |
Congressional Trades
1 members: 4 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
8 institutional holders with $2.1B total value (27,401,666 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, CHARLES. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 16,862,691 | $1.3B | 61.5% | — |
| 2 | FMR LLC | 2,390,362 | $182.8M | 8.7% | ADD +40.5% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,964,419 | $150.3M | 7.2% | ADD +44.6% |
| 4 | TWO SIGMA INVESTMENTS, LP | 1,947,047 | $148.9M | 7.1% | DOUBLED +177.4% |
| 5 | NORGES BANK | 1,527,028 | $116.8M | 5.6% | NEW |
| 6 | MORGAN STANLEY | 1,399,809 | $107.1M | 5.1% | ADD +32.7% |
| 7 | BANK OF AMERICA CORP /DE/ | 1,078,048 | $82.5M | 3.9% | ADD +25.4% |
| 8 | WELLS FARGO & COMPANY/MN | 232,262 | $17.8M | 0.8% | ADD +55.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 1,700,747 | 2,390,362 | +40.5% | $182.8M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,527,028 | — | $116.8M | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,054,865 | 1,399,809 | +32.7% | $107.1M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 149,121 | 232,262 | +55.8% | $17.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 322,246 | 0 | -100.0% | $0.00 | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,331,473 | 1,925,198 | +44.6% | $100.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,101,509 | 1,380,868 | +25.4% | $71.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 245,946 | 322,246 | +31.0% | $16.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 427,489 | 149,121 | -65.1% | $7.7M | 2025-Q3 |
| NORGES BANK | EXIT | 1,956,654 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 843,321 | 2,339,067 | +177.4% | $101.0M | 2025-Q2 |
| NORGES BANK | NEW | — | 1,956,654 | — | $84.5M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 101,435 | 427,489 | +321.4% | $18.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 245,946 | — | $10.6M | 2025-Q2 |
| Duquesne Family Office LLC | EXIT | 438,050 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 1,938,561 | 3,416,533 | +76.2% | $118.1M | 2025-Q1 |
| FMR LLC | ADD | 1,621,595 | 2,175,799 | +34.2% | $75.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 238,536 | 843,321 | +253.5% | $29.2M | 2025-Q1 |
| Duquesne Family Office LLC | NEW | — | 438,050 | — | $15.1K | 2025-Q1 |
| NORGES BANK | EXIT | 1,065,479 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 3,403,014 | 1,938,561 | -43.0% | $53.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 69,678 | 88,000 | +26.3% | $2.4M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,284,802 | — | $32.7M | 2024-Q3 |
6 unique insiders with 17 transactions. Net insider value: -$11.0M ($0.00 bought, $11.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Kumar Neil | Chief Executive Officer | SELL | 7,147 | $67.20 | $480.3K |
| Jun 4, 2026 | Kumar Neil | Chief Executive Officer | SELL | 2,200 | $65.72 | $144.6K |
| May 21, 2026 | Kumar Neil | Chief Executive Officer | SELL | 2,256 | $67.57 | $152.4K |
| May 18, 2026 | Trimarchi Thomas | President and CFO | SELL | 10,456 | $64.82 | $677.7K |
| May 16, 2026 | Apuli Maricel | Chief Accounting Officer | F | 4,714 | $66.13 | $311.7K |
| May 16, 2026 | Kumar Neil | Chief Executive Officer | M | 33,544 | $0.00 | $0.00 |
| May 16, 2026 | Kumar Neil | Chief Executive Officer | F | 36,236 | $66.13 | $2.4M |
| May 16, 2026 | Trimarchi Thomas | President and CFO | F | 22,781 | $66.13 | $1.5M |
| May 16, 2026 | Kumar Neil | Chief Executive Officer | M | 33,544 | $0.00 | $0.00 |
| May 15, 2026 | Scott Randal W. | Director | SELL | 6,200 | $66.69 | $413.5K |
| May 15, 2026 | Scott Randal W. | Director | M | 10,000 | $0.00 | $0.00 |
| May 15, 2026 | Scott Randal W. | Director | M | 10,000 | $16.75 | $167.5K |
| May 8, 2026 | Kumar Neil | Chief Executive Officer | SELL | 13,973 | $66.65 | $931.3K |
| May 7, 2026 | Kumar Neil | Chief Executive Officer | SELL | 11,217 | $67.50 | $757.1K |
| Apr 30, 2026 | Apuli Maricel | Chief Accounting Officer | SELL | 2,000 | $71.58 | $143.2K |
| Apr 10, 2026 | Kumar Neil | Chief Executive Officer | SELL | 20,000 | $74.60 | $1.5M |
| Apr 9, 2026 | Kumar Neil | Chief Executive Officer | SELL | 7,200 | $73.64 | $530.2K |
| Mar 18, 2026 | Trimarchi Thomas | President and CFO | A | 59,041 | $0.00 | $0.00 |
| Mar 18, 2026 | Apuli Maricel | Chief Accounting Officer | A | 14,170 | $0.00 | $0.00 |
| Mar 17, 2026 | Kumar Neil | Chief Executive Officer | A | 40,570 | $0.00 | $0.00 |
| Mar 17, 2026 | Kumar Neil | Chief Executive Officer | A | 104,313 | $0.00 | $0.00 |
| Mar 13, 2026 | Kumar Neil | Chief Executive Officer | SELL | 9,690 | $68.36 | $662.4K |
| Mar 12, 2026 | Kumar Neil | Chief Executive Officer | SELL | 14,337 | $68.48 | $981.8K |
| Mar 10, 2026 | Valantine Hannah | Director | M | 8,671 | $0.00 | $0.00 |
| Mar 10, 2026 | Valantine Hannah | Director | SELL | 8,671 | $72.00 | $624.3K |
| Mar 10, 2026 | Valantine Hannah | Director | M | 8,671 | $27.36 | $237.2K |
| Mar 4, 2026 | Ellis Andrea | Director | M | 64,921 | $8.45 | $548.6K |
| Mar 4, 2026 | Ellis Andrea | Director | M | 64,921 | $0.00 | $0.00 |
| Feb 27, 2026 | Valantine Hannah | Director | M | 25,484 | $0.00 | $0.00 |
| Feb 27, 2026 | Valantine Hannah | Director | M | 25,484 | $48.45 | $1.2M |
| Feb 26, 2026 | Apuli Maricel | Chief Accounting Officer | SELL | 2,000 | $66.00 | $132.0K |
| Feb 19, 2026 | Kumar Neil | Chief Executive Officer | SELL | 18,923 | $71.03 | $1.3M |
| Feb 11, 2026 | Kumar Neil | Chief Executive Officer | SELL | 7,806 | $70.69 | $551.8K |
| Feb 10, 2026 | Kumar Neil | Chief Executive Officer | SELL | 14,201 | $71.80 | $1.0M |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 3 mixed, 4 neutral. Avg impact: 4.9/10.
BEARISH
CLUSTER
5/10
Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market
May 26, 2026
NEUTRAL
144
3/10
BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 s
May 21, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 e
May 19, 2026
MIXED
S-3ASR
6/10
BridgeBio Pharma filed an automatic shelf registration (S-3ASR) to register an unlimited amount of s
May 8, 2026
MIXED
PRESS-RELEASE
6/10
BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus) driven by $180.6M in Attruby
May 7, 2026
NEUTRAL
DEFA14A
4/10
Analysis based on filing metadata only — document content was unavailable
Apr 24, 2026
NEUTRAL
CLUSTER
3/10
BridgeBio Pharma CEO Kumar Neil was granted a total of 144,883 shares in non-cash awards and sold 9,
Mar 19, 2026
BEARISH
CLUSTER
7/10
BridgeBio Pharma CEO Kumar Neil sold shares worth over $1.6 million in open-market transactions, whi
Mar 16, 2026
MIXED
8-K
7/10
BridgeBio Pharma reported strong 2025 financial results driven by $502.1 million in net revenue, pri
Feb 24, 2026
BULLISH
8/10
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a P
May 27, 2026
BULLISH
8/10
BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 C
May 12, 2026
BULLISH
8/10
BridgeBio presented new acoramidis data at Heart Failure 2026, showing a 34% reduction in cardiovasc
May 11, 2026
BULLISH
7/10
BridgeBio Pharma announced that Brazilian health regulator ANVISA approved acoramidis (BEYONTTRA) fo
May 6, 2026
NEUTRAL
3/10
BridgeBio Pharma announced it will present additional Phase 3 data for encaleret in ADH1 at the 2026
May 5, 2026
BULLISH
8/10
BridgeBio Pharma presented positive interim Phase 3 FORTIFY trial results for BBP-418, an oral thera
Mar 11, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 29 analysts: 8 strong buy, 19 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$102.71 mean target
+51.8% upside
Strong Buy (1.42)
$76.00 Low
$157.00 High
| Metric | Value |
|---|---|
| Current Price | $67.68 |
| Target Low | $76.00 |
| Target Mean | $102.71 |
| Target Median | $100.00 |
| Target High | $157.00 |
| # Analysts | 23 |
| Recommendation | Strong Buy (1.42) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.56 | $-0.70 | $-0.42 | 40.6% | +6.9% | 0↑ 3↓ | $0.2B | 103.8% | 6 |
| Next Q 2026-09-30 |
$-0.46 | $-0.57 | $-0.37 | 36.3% | +6.8% | 2↑ 1↓ | $0.3B | 110.3% | 6 |
| Current FY 2026-12-31 |
$-2.17 | $-2.62 | $-1.49 | 42.5% | -6.3% | 3↑ 1↓ | $1.0B | 92.2% | 8 |
| Next FY 2027-12-31 |
$0.33 | $-1.30 | $2.12 | 115.3% | +21.8% | 2↑ 1↓ | $1.6B | 68.3% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.565 | |
| 7d ago | $-0.576 | +0.011 |
| 30d ago | $-0.607 | +0.042 |
| 60d ago | $-0.522 | -0.042 |
| 90d ago | $-0.390 | -0.175 |
15 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 6 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| May 28, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 26, 2026 | Raymond James | DOWNGRADE | Outperform | Market Perform |
| May 19, 2026 | Citigroup | INITIATE | — | Neutral |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 8, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Apr 29, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 29, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 28, 2026 | Mizuho | REITERATE | Outperform | Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 9, 2026 | RBC Capital | INITIATE | — | Outperform |
| Mar 18, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 10, 2026 | William Blair | INITIATE | — | Outperform |
| Feb 25, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 17, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 28, 2026 | Barclays | INITIATE | — | Overweight |
| Jan 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Morgan Stanley | INITIATE | — | Overweight |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 19 | 2 | 0 | 0 | 93% | |
| May 1, 2026 | 9 | 20 | 1 | 0 | 0 | 97% | |
| Apr 1, 2026 | 9 | 19 | 1 | 0 | 0 | 97% | |
| Mar 1, 2026 | 8 | 19 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 8 | 19 | 1 | 0 | 0 | 96% | |
| Jan 1, 2026 | 8 | 17 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 4 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | May 11, 2026 (13d) |
| Mar 19, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | Apr 8, 2026 (21d) |
| Mar 18, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | Apr 8, 2026 (22d) |
| Mar 3, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | BRIDGEBIO PHARMA INC | Apr 8, 2026 (37d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Nov 27, 2026
fda_pdufa
PDUFA: BBIO — BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) — 2026-11-27
FDA target action date 2026-11-27 for BBIO (BridgeBio Pharma, Inc.). Drug: BBP-418. Indication: limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Jun 2, 2026
short_volume
Short Volume: BBIO — 74.2% short (1.9M / 2.6M)
Short: 1,900,639 | Exempt: 151 | TRF Vol: 2,561,094 | Short Ratio: 74.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: BBIO — 90.0% short (5.3M / 5.9M)
Short: 5,286,891 | Exempt: 0 | TRF Vol: 5,875,118 | Short Ratio: 90.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
fda
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
<p><em>- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority R
May 18, 2026
short_volume
Short Volume: BBIO — 57.2% short (1.0M / 1.8M)
Short: 1,012,651 | Exempt: 213,236 | TRF Vol: 1,770,065 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 12, 2026
fda
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
<p><em>- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of enca
May 11, 2026
fda
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
<p><em>-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated w
May 8, 2026
other
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p>PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical com
May 8, 2026
short_volume
Short Volume: BBIO — 60.9% short (1.5M / 2.4M)
Short: 1,461,454 | Exempt: 1,694 | TRF Vol: 2,397,841 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
<p>PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, mul
May 7, 2026
earnings_calendar
BBIO Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
other
BridgeBio to Participate in May and June Investor Conferences
<p align="left">PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharm
May 6, 2026
fda
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
<p><em>- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the mo
May 5, 2026
fda
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
<p>PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical com
May 5, 2026
short_interest
FTD: BBIO — 20,622 shares ($1.4M) failed to deliver
Settlement: 20260505, Price: $68.99, FTD Value: $1,422,711.78, BRIDGEBIO PHARMA INC COM